InMed Net Working Capital from 2010 to 2024

INM Stock  USD 5.26  0.11  2.14%   
InMed Pharmaceuticals Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to grow to about 7.1 M this year. During the period from 2010 to 2024, InMed Pharmaceuticals Net Working Capital quarterly data regression pattern had sample variance of 16.6 T and median of  5,055,397. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
6.7 M
Current Value
7.1 M
Quarterly Volatility
4.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 634.7 K, Interest Expense of 153.3 K or Selling General Administrative of 5.5 B, as well as many indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 0.0 or Days Sales Outstanding of 36.24. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

Latest InMed Pharmaceuticals' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of InMed Pharmaceuticals over the last few years. It is InMed Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Pretty Stable
   Net Working Capital   
       Timeline  

InMed Net Working Capital Regression Statistics

Arithmetic Mean7,208,549
Geometric Mean6,536,599
Coefficient Of Variation56.54
Mean Deviation2,701,005
Median5,055,397
Standard Deviation4,075,752
Sample Variance16.6T
Range15M
R-Value0.24
Mean Square Error16.9T
R-Squared0.06
Significance0.39
Slope216,820
Total Sum of Squares232.6T

InMed Net Working Capital History

20247.1 M
20236.7 M
20229.3 M
20216.3 M
20206.2 M
20194.6 M
201812.9 M

About InMed Pharmaceuticals Financial Statements

InMed Pharmaceuticals investors utilize fundamental indicators, such as Net Working Capital, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital6.7 M7.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
230.4
Revenue Per Share
0.603
Quarterly Revenue Growth
(0.45)
Return On Assets
(0.39)
Return On Equity
(0.72)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.